Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
Results of the Special Meeting
At the Special Meeting, Onconetix's stockholders approved the following proposals:
an amendment to the Onconetix, Inc. Amended and Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-10 to 1-for-150, at any time prior to the one-year anniversary date of the Special Meeting, with such ratio to be determined by the Board without further approval or authorization of the stockholders; and
the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. (the 'Adjournment Proposal').
Final voting results from the Special Meeting were reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'SEC') on June 5, 2025.
Reverse Stock Split
In conjunction with stockholder approval of the reverse stock split, the Company's Board of Directors determined to fix a split ratio of 1-for-85 shares. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on June 13, 2025. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'ONCO' under the new CUSIP number 68237Q203. The reverse stock split is intended to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market.
At the effective time of the reverse split, every 85 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be canceled with the holders thereof receiving cash compensation. The amount of compensation will be determined by multiplying the fractional share by the closing price per share of the Company's common stock on The Nasdaq Capital Market at the close of business on the trading day prior to the effective date of the reserve stock split, or June 12, 2025. The reverse split will have no effect on the number of authorized shares of the Company's common stock, and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. The reverse stock split will additionally apply to the Company's common stock issuable upon exercise or conversion of the Company's equity awards, convertible preferred stock and warrants, as well as the applicable exercise price.
The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 44.4 million to approximately 521,863.
About Onconetix, Inc.
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation. The Company also owns ENTADFI, an FDA-approved, once-daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia, a disorder of the prostate. For more information, visit www.onconetix.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements (including, without limitation, statements regarding the timing and effectiveness of the anticipated reverse split and compliance with applicable Nasdaq continued listing requirements) are based on Onconetix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions; whether the Company will be able to regain and maintain compliance with Nasdaq's applicable listing criteria and the effect of a delisting from Nasdaq on the market for the Company's securities; whether a definitive agreement for the proposed transaction with Ocuvex Therapeutics, Inc. ('Ocuvex') and any related financing will be entered into; whether such transactions, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of a proposed transaction with Ocuvex; Onconetix's ability to integrate the assets and commercial operations contemplated to be acquired from Ocuvex into the Company's business; risks related to Onconetix's ability to commercialize or monetize Proclarix and integrate the assets and commercial operations; risks related to the Company's present need for capital to commercially launch Proclarix and have adequate working capital; risks related to Onconetix's ability to attract, hire and retain skilled personnel necessary to commercialize and operate the Company's commercial products; the failure to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix's products; risks related to the Company's ability to obtain and maintain intellectual property protection for its current products; and the Company's reliance on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix's Annual Report on Form 10-K, filed with the SEC on June 2, 2025 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
For more information:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Investor Contact Information:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 minutes ago
- Globe and Mail
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience. Earlier this week, AbbVie signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value of nearly $2.1 billion. The transaction, expected to be completed in the third quarter, will add Capstan's lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to its immunology pipeline. The acquisition will also add Capstan's proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body. Since the beginning of last year, the company has signed over 20 early-stage deals, including promising technologies and innovative mechanisms that can elevate the standard of care across various therapeutic areas. Earlier this year, AbbVie acquired rights to develop a long-acting amylin analog for the treatment of obesity from Denmark's Gubra, marking its foray into the obesity space. It also plans to invest further in obesity. Among some recent larger deals, AbbVie acquired ImmunoGen, which added the ovarian cancer drug Elahere and neuroscience drugmaker Cerevel Therapeutics last year. These acquisitions have not only broadened AbbVie's therapeutic footprint but also diversified its pipeline across multiple modalities. The augmented pipeline now includes next-generation immunology candidates, bispecifics, antibody-drug conjugates and innovative therapies for neuropsychiatric and neurodegenerative disorders. We believe ABBV will continue pursuing such deals to further grow its pipeline. Focus on M&A in 2025 While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making this year, Big Pharma continues to pursue strategic assets in key growth areas. Last month, Eli Lilly LLY announced its intent to acquire cardiology-focused Verve Therapeutics in a deal valued at up to $1.3 billion. This transaction, which is also expected to close in the third quarter, will mark LLY's third targeted M&A deal this year. Earlier in January, it signed a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug. In May, Lilly agreed to acquire SiteOne Therapeutics for $1 billion to strengthen its neuroscience pipeline. Such deals suggest that LLY's M&A strategy is selective, focusing on long-term strength across therapeutic areas beyond its dominant presence in obesity. In June, Sanofi SNY announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on the blockbuster drug Dupixent. Through this transaction, SNY intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Recently, Sanofi completed the acquisition of an investigational bispecific antibody targeting autoimmune diseases from California-based Dren Bio and also agreed to acquire neurology-focused Vigil Neuroscience in a deal valued at around $470 million. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.42 times forward earnings, slightly lower than its industry's average of 14.86. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.46. The Zacks Consensus Estimate for 2025 EPS has risen from $12.26 to $12.28, while that for 2026 has remained consistent at $14.06 over the past 60 days. AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report This article originally published on Zacks Investment Research (
CTV News
7 minutes ago
- CTV News
Elon Musk wants to create a new political party. Building rockets may be easier
(Elon Musk looks on during a news conference with U.S. President Donald Trump in the Oval Office on May 30. Allison Robbert/AFP/Getty Images via CNN Newsource) Elon Musk has started multiple successful companies that have accomplished incredible technological feats. His latest ambition may be significantly more difficult to achieve: starting a new American political party for the masses. Citing his disappointment in U.S. President Donald Trump and his massively expensive domestic policy bill, Musk said he would form the 'America party' the day after the 'Big, Beautiful Bill' passes, if Congress approves it. Musk has called Democrats and Republicans the 'uniparty' because government deficits have risen dramatically under administrations and Congresses controlled by both parties. He says he wants to build a fiscally conservative party that reins in spending – although he's presented few other details of what the party's platform might be. Experts in campaign finance and political science say there's a reason no third party has ever truly successfully challenged America's two-party system: It is financially and legally difficult to create a new party, and voters and candidates are hesitant to join. 'Third-party movements in the US have generally arisen out of some sort of set of deep-seated grievances,' Emory University political science professor Alan Abramowitz told CNN. 'It was not just some wealthy person who's decided they wanted to start a third party.' It's not clear how much if any preparation has been done to stand up the party. A spokesperson for Musk's political action committee, America PAC, declined to comment. A senior White House official brushed off Musk's criticism of the bill. 'No one really cares what he says anymore,' the source said. Two Republicans close to the White House said that it was also unclear how Musk's threats might play out in the midterm elections. 'Of course, members don't want to be primaried,' one of the sources said. 'It's unclear if he's actually going to get involved. A few weeks ago he apologized and called Trump.' Musk may be the richest person on Earth, but he could also encounter some financial resistance himself. Former DOGE adviser and Trump supporter James Fishback said he is launching his own super PAC to counter Musk's money in congressional races. Fishback, who runs an investment firm, said he will provide $1 million in initial funding to the super PAC, which will be called FSD PAC, an abbreviation for Full Support for Donald. He told CNN that the super PAC will work to back Trump's agenda 'and against anyone who threatens to sabotage that agenda,' including Musk. Legal hurdles American political parties are governed by laws and rules not just from the Federal Election Commission but also from the states, including around which parties can appear on ballots. 'The system is sort of set up to almost make it impossible for third parties to be successful,' Abramowitz said. Funding a new party has its own hurdles. The McCain-Feingold Bipartisan Campaign Reform Act of 2022 set strict limits on donations to political parties. The current limit is just under $450,000 spread across different party purposes. Musk would need thousands of co-donors to help him fund his party, said Lee Goodman, an attorney and former chair of the FEC. 'One very wealthy individual cannot capitalize a new national political party, the way he might start a business, because of federal contribution limits,' Goodman told CNN. 'The prospect of a wealthy founder seed funding a national party to participate in federal elections around the country is not feasible in the current regulatory system.' Bradley Smith, another former FEC chair and who is now a law professor at Capital University Law School, said there are some ways around the current regulations. 'There is some case law suggesting that some of the organizational activities of a party and starting a party right can be funded with larger contributions, until it actually qualifies for party status under the election commission regulations,' Smith said, but he noted it's complex and difficult to do. 'You can fund super PACs all you want. But you can't fund a political party, as a strange part of American law,' he added. Super PACs are not legally allowed to coordinate spending with parties or candidates, although previous candidates have tested these limits, as nothing prohibits coordination when the information is shared publicly. 'Coordination has, in fact, become commonplace,' the nonpartisan Campaign Legal Center has said. Then there's getting on the actual ballots. States have different rules, such as requiring a certain number of signatures. 'It would take years and might require changes in laws around the country that currently favor two major political parties,' Goodman noted Political hurdles Beyond the legal and logistical hurdles, there's convincing candidates to join and voters to cast their ballots for them. Despite varying approval levels, party loyalties remain strong, Abramowitz said, especially among Republicans, who have coalesced around Trump. 'The biggest obstacle is just that it's very difficult to convince people to vote for a third-party candidate because the argument is always 'you're wasting your vote. You're voting for someone who has no chance of winning elections,'' Abramowitz said. Candidates may also be wary. Democrats are unlikely to run under the America Party because 'Democrats hate Elon Musk,' Abramowitz said. And Republicans 'have clearly shown that they're much more attached to Donald Trump than they are to Elon Musk.' Republicans highly approve of Trump, according to CNN Chief Data Analyst Harry Enten's aggregation of available polling data. Some 90 precent of Republicans approve of Trump's performance thus far in this presidency, and he is doing better in approval ratings five months into the presidency than former Republican presidents. And in 96 per cent of the 2024 primary races where Trump endorsed, those candidates won. If creating a new political party proves too difficult, Musk could still hold a lot of sway through his super PAC, to which he can send unlimited funds. That PAC can then support independent candidates, who could also have an easier time getting on ballots. 'Independent spending, individually or via a super PAC, remains the most legal and practical mechanism for a wealthy individual to have a say in national politics,' Goodman said. Article written by Hadas Gold, CNN CNN's Kristen Holmes and Fredreka Schouten contributed reporting.
CTV News
9 minutes ago
- CTV News
Chuck E. Cheese is opening arcades for adults
Chuck E. Cheese isn't just for the kids anymore. The arcade chain is opening a spin-off aimed at adults, called 'Chuck's Arcade,' which the company describes as a 'modern-day love letter to the games and people who made Chuck E. Cheese great.' Similar to the kiddie version, Chuck's Arcade has a mix of nostalgic arcade games, like Donkey Kong and Mortal Kombat; and newer titles such as Halo and Connect Four Hoops. Plus, each arcade is 'overseen' by one of the chain's iconic animatronic characters, including Chuck E. Cheese himself or other characters from his Munch's Make Believe Band. Ten are open so far at malls across the United States, with arcades in St. Petersburg, Florida; Tulsa, Oklahoma; El Paso, Texas; and St. Louis. Each location looks different, decorated with original artwork that celebrates the brand's past, according to a release. Of course, there will also be prizes for adults to win and arcades will have 'old-school merch' available for purchase. Some arcades will serve food, with the Kansas City location having a pizzeria that also serves a small selection of beer and wine, a spokesperson told CNN. David McKillips, CEO of Chuck. E. Cheese, said that the spin-off is a 'natural evolution' for the company following the remodel of its 500 locations and sees it as an 'opportunity to extend our arcade legacy into new formats that engage both lifelong fans and a new generation through a curated mix of retro classics and cutting-edge experiences.' The company's expansion comes five years after it filed for bankruptcy during the height of the Covid-19 pandemic. Chuck E. Cheese spent $350 million in remodels over the past few years as well as introducing new pricing tiers to attract budget-focused families. The launch of Chuck's Arcade comes amid troubles for its chief rival Dave & Buster's. The latter is publicly traded and recently reported a 9.4 per cent decline in same-store sales, with its new management trashing 'ill-advised changes' implemented by its previous leadership that included too many adjustments at once. Article written by Jordan Valinsky, CNN
